RxDoctor Payments Data

Shazia Billal, MD

Family Medicine · Shenandoah, TXNPI 1144270448

Payments from drug & device makers

$14,569in general payments, 2019–2025

Across 759 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$976
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,2008%
  • Food & beverage$13,15790%
  • Education$2121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca89$1,862
AbbVie(2 entities)77$1,263
Biohaven Pharmaceuticals, Inc.2$1,219
Novo Nordisk75$1,150
GSK68$1,140
Lilly USA, LLC69$976
Otsuka America Pharmaceutical, Inc.35$639
Amgen(2 entities)34$588
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC31$489
Bayer18$422
Pfizer26$365
Boehringer Ingelheim15$258
Novartis15$257
Astellas Pharma US Inc7$253
Amarin Pharma, Inc.13$228
Esperion Therapeutics, Inc.13$214
Hologic Sales And Service, LLC4$188
Dexcom, Inc.11$179
Eisai Inc.11$177
Merck11$165
Johnson & Johnson(2 entities)9$151
Paratek Pharmaceuticals, Inc.8$139
Sunovion Pharmaceuticals Inc.9$135
Exact Sciences6$129
Abbott7$127
Medinc Of Texas2$102
Vivus LLC6$100
Vertiflex, Inc.6$96
Orexo US, Inc.5$96
Biohaven Pharmaceutical Holding Company Ltd.4$94
Gilead5$94
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$87
Scynexis, Inc.4$84
Indivior Inc.4$74
Takeda Pharmaceuticals U.S.A., Inc.5$74
Boston Scientific3$73
Nestle Healthcare Nutrition Inc.3$69
Neurocrine Biosciences, Inc.2$55
Ironwood Pharmaceuticals, Inc3$53
Kowa Pharmaceuticals America, Inc.3$52
Melinta Therapeutics, LLC2$51
Avanir Pharmaceuticals, Inc.3$44
Idorsia Pharmaceuticals US Inc3$41
Teva Pharmaceuticals USA, Inc.2$39
Upsher-smith Laboratories LLC2$39
MDD US Operations, LLC2$38
Alk-abello, Inc2$33
Shire North American Group Inc2$33
Mayne Pharma Commercial LLC1$32
Assertio Therapeutics, Inc.2$28
Shield Therapeutics Inc1$23
Nevro Corp.1$23
Vanda Pharmaceuticals Inc.1$20
Corcept Therapeutics1$19
Organon1$19
Genentech USA, Inc.1$18
Kyowa Kirin, Inc.1$17
Biogen1$17
Ironshore Pharmaceuticals Inc.1$16
Currax Pharmaceuticals LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,569 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$80,952
Medicare patients
101
Services billed
1,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$107,455
JardianceEmpagliflozin71$80,997
FarxigaDapagliflozin Propanediol68$78,280
MounjaroTirzepatide46$59,836
JanumetSitagliptin Phos/Metformin Hcl47$53,817
EliquisApixaban44$53,290
JanuviaSitagliptin Phosphate30$48,681
TrulicityDulaglutide24$46,055
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$37,902
XifaxanRifaximin11$29,422
Abilify MaintenaAripiprazole12$23,682
LinzessLinaclotide13$12,129
VascepaIcosapent Ethyl17$11,644
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl63$10,381
Repatha SyringeEvolocumab11$9,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Belsomra$165$107,88089 claims
Novo NordiskOzempic$1,150$107,45587 claims
Lilly USA, LLCMounjaro, Trulicity$976$105,89170 claims
Boehringer IngelheimJardiance$258$80,99771 claims
AstraZenecaFarxiga$1,862$78,28068 claims
PfizerEliquis$365$53,29044 claims
GSKTrelegy Ellipta$1,140$37,90238 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$489$29,42211 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$639$23,68212 claims
AbbVieLinzess$1,263$12,12913 claims
Johnson & JohnsonXarelto$151$6,39211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →